LabCorp pays $85.3M to add LDL testing to its portfolio
LabCorp will pay $85.3 million to buy LipoScience, a company that uses nuclear magnetic resonance (NMR) to conduct cardiovascular diagnostic tests.
LipoScience markets a proprietary test that quantifies low-density lipoprotein (LDL) cholesterol. It uses NMR technology to identify lipoproteins and small molecules to diagnose cardiovascular and metabolic disorders.
The acquisition is expected to fortify LabCorp’s clinical decision support and testing programs. The companies plan to close the deal in the fourth quarter of 2014.